| 1 |
30307354 | Afatinib treatment for her-2 amplified metastatic colorectal cancer based on patient-derived xenograft models and next generation sequencing. | 2019 |
1 |
| 2 |
30792807 | Anticancer response to disulfiram may be enhanced by co-treatment with MEK inhibitor or oxaliplatin: modulation by tetrathiomolybdate, KRAS/BRAF mutations and c-MYC/p53 status. | 2019 |
1 |
| 3 |
30565584 | [Perioperative treatment with FOLFIRI plus aflibercept in a patient with RAS and BRAF wild-type, left-sided colon cancer, with early relapse following adjuvant oxaliplatin- based treatment due to potentially resectable liver metastases]. | 2018 Nov |
1 |
| 4 |
28040715 | Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. | 2017 Jan |
1 |
| 5 |
28418176 | Panitumumab-Conjugated Pt-Drug Nanomedicine for Enhanced Efficacy of Combination Targeted Chemotherapy against Colorectal Cancer. | 2017 Jul |
1 |
| 6 |
28101205 | Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation. | 2016 Dec |
1 |
| 7 |
24889488 | KRAS mutation is associated with worse prognosis in stage III or high-risk stage II colon cancer patients treated with adjuvant FOLFOX. | 2015 Jan |
1 |
| 8 |
25666295 | FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study. | 2015 Jun |
1 |
| 9 |
23821376 | Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. | 2014 Jun |
2 |
| 10 |
20146801 | TAp73 is one of the genes responsible for the lack of response to chemotherapy depending on B-Raf mutational status. | 2010 Feb 10 |
2 |